IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas

Valera, Alexandra; Balagué, Olga; Colomo, Luís; Martı́nez, Antonio; Delabie, Jan; Taddesse-Heath, Lekidelu; Jaffe, Elaine S.; Campo, Elı́as

doi:10.1097/pas.0b013e3181f3e29f

Cited by 241 publications

(254 citation statements)

References 39 publications

Supporting

Mentioning

239

Contrasting

Order By: Relevance

“…Most PBLs are positive for EBER (78%) with a predominance of type I latency pattern in contrast with type II and type III in EBV1 DLBCL of the elderly. By FISH, MYC rearrangement is detected in about 50% of cases; the most common partner is IgH [20]. Of note, MYC rearrangement was more commonly seen in EBER-positive PBL compared with EBER-negative PBL.…”

Section: Differential Diagnosismentioning

confidence: 99%

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

et al. 2016

View full text Add to dashboard Cite

Epstein–Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly is a provisional entity included in the 2008 WHO classification of lymphoid neoplasms. It is a disease typically seen in the elderly and thought to be associated with chronic EBV infection and severe immunosuppression with a component of immunosenescence. Recent research, however, has suggested that EBV‐positive DLBCL can be seen in younger, immunocompetent patients.The diagnosis of EBV‐positive DLBCL of the elderly is made through a careful pathological evaluation. The differential diagnosis includes infectious mononucleosis (specifically in younger patients), lymphomatoid granulomatosis, Hodgkin lymphoma, and gray zone lymphoma, among others. Detection of EBV‐encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined.The International Prognostic Index (IPI), and the Oyama score can be used for risk‐stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 is emerging as a potential adverse, and targetable, prognostic factor.Patients with EBV‐positive DLBCL should be staged and managed following similar guidelines than patients with EBV‐negative DLBCL. It has been suggested, however, that EBV‐positive patients have a worse prognosis than EBV‐negative counterparts in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV‐positive DLBCL. Am. J. Hematol. 91:530–537, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Section: Differential Diagnosismentioning

confidence: 99%

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In fact, recent studies, including the frequent presence of MYC translocations in PBL, point to a close relationship between PBL and plasmablastic transformation of PCM. 55,56 These observations may affect future therapeutic approaches to this disease.…”

Section: Diffuse Large B-cell Lymphomasmentioning

confidence: 99%

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo

Swerdlow

Harris

et al. 2011

Blood

Self Cite

1,779

1,414

View full text Add to dashboard Cite

The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of distinct diseases, using a multidisciplinary approach. The updated classification refined the definitions of well-recognized diseases, identified new entities and variants, and incorporated emerging concepts in the understanding of lymphoid neoplasms. However, some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities, categories for which the World Health Organization working groups felt there was insufficient evidence to recognize as distinct diseases at this time. In addition, since its publication, new findings and ideas have been generated. This review summarizes the scientific rationale for the classification, emphasizing changes that have had an effect on practice guidelines. The authors address the criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly. The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities, is reviewed. These new observations chart a course for future research in the field. (Blood. 2011

show abstract

“…For the break-apart probes, the cut-off values were 3% for the detection of the rearrangements and 6% to detect gains. For the dual fusion probe, a cutoff of 11% for both structural and numerical abnormalities was considered (43).…”

Section: Translational Relevancementioning

confidence: 99%

MYD88L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome

Rovira

Karube

Valera

et al. 2016

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: Mutations in MYD88 are found in different lymphoproliferative disorders associated with particular biologic characteristics and clinical impact. The aim of this study was to analyze the incidence of MYD88 mutations and its clinical impact in diffuse large B-cell lymphoma (DLBCL).Experimental Design: The incidence, clinicobiological features, and outcome of 213 patients (115 M/98 F; median age, 65 years) with DLBCL treated with immunochemotherapy in a single institution according to MYD88 mutational status as assessed by an allele-specific PCR assay were analyzed. The cell of origin (COO) was determined in 129 cases by gene expression.Results: MYD88 mutations were found in 47 cases (22%), including L265P in 39 and S219C and M232F in 4 cases, respectively. Patients with MYD88 L265P were older, presenting frequent extranodal involvement, and mostly corresponded to activated B-cell like (ABC) subtype, whereas no preference in COO was observed in patients with other MYD88 mutations. Five-year overall survival (OS) for MYD88 wildtype, MYD88 L265P, and other variants was 62%, 52%, and 75%, respectively (P ¼ 0.05). International Prognostic Index (IPI) (HR, 2.71; P < 0.001) and MYD88 L265P (HR, 1.786; P ¼ 0.023) were independent variables predicting OS in the multivariate analysis. However, MYD88 L265P lost its independent value when COO was included in the model.Conclusions: Our findings indicate that MYD88 L265P mutations, but no other variants, identify a subgroup of DLBCL mainly of ABC origin, with extranodal involvement and poor outcome.

show abstract

IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas

Cited by 241 publications

References 39 publications

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

MYD88L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome

Contact Info

Product

Resources

About